Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × Letrozole × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 336 Neoplasm Metastasis 19 Neoplasms 10 Advanced Breast Cancer 9 Carcinoma, Intraductal, Noninfiltrating 7 Carcinoma, Ductal, Breast 7 Osteoporosis 6 Breast Neoplasms, Male 6 Breast Diseases 6 Triple Negative Breast Neoplasms 5 Carcinoma, Lobular 5 Breast Carcinoma In Situ 5 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Arthralgia 4 Recurrence 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Neoplasms, Hormone-Dependent 3 Squamous Cell Carcinoma of Head and Neck 2 Pain 2 Obesity 2 Neoplasms by Site 2 Multiple Endocrine Neoplasia Type 1 2 Infertility 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Endometrial Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06953882 2025-07-14

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡